Get started
Author

Bradley Raybold

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
2019 · Guru Sonpavde, Andrea Necchi, et al. · Future Oncology · 98
PDF
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study
2023 · Mark D. Tyson, David Morris, et al. · The Journal of Urology · 37
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial
2022 · Siamak Daneshmand, Iris S.G. Brummelhuis, et al. · Urologic Oncology Seminars and Original Investigations · 35
PDF
A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.
2020 · Noah M. Hahn, Sam Chang, et al. · Journal of Clinical Oncology · 14
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC).
2019 · Guru Sonpavde, Andrea Necchi, et al. · Journal of Clinical Oncology · 10
SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy.
2023 · Sarah P. Psutka, Christopher Cutie, et al. · Journal of Clinical Oncology · 9
A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.
2019 · Noah M. Hahn, Sam S. Chang, et al. · Journal of Clinical Oncology · 8
A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder.
2021 · Stephen B. Williams, Christopher Cutie, et al. · Journal of Clinical Oncology · 6
A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT
2019 · J.A. Witjes, J. Gschwend, et al. · European Urology Supplements · 4
Mp13-17 Sunrise-2: a Phase 3, Multicenter, Randomized Study Evaluating the Efficacy of Tar-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
2021 · Stephen Williams, Christopher Cutie, et al. · The Journal of Urology · 3
SunRISe-2: a phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder
2021 · S. Williams, C. Cutie, et al. · European Urology Open Science · 2
A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).
2020 · Guru Sonpavde, Andrea Necchi, et al. · Journal of Clinical Oncology · 2
Reply by Authors
2023 · Mark D. Tyson, David Morris, et al. · The Journal of Urology
Works count: 13
Citation count: 228
H-index: 7
I10-index: 5
Year
Topic
Type